AZN
AstraZeneca PLC
Income statement
| USDLine, in USD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 58.7B | 54.1B | 45.8B | 44.4B | 37.4B | 26.6B | 24.4B | 22.1B | 22.5B | 23.0B | 24.7B |
Cost of revenue | 10.6B | 10.2B | 8.3B | 12.4B | 12.4B | 5.3B | 4.9B | 4.9B | 4.3B | 4.1B | 4.6B |
| Gross profit | 48.1B | 43.9B | 37.5B | 32.0B | 25.0B | 21.3B | 19.5B | 17.2B | 18.1B | 18.9B | 20.1B |
| 14.2B | 13.6B | 10.9B | 9.8B | 9.7B | 6.0B | 6.1B | 5.9B | 5.8B | 5.9B | 6.0B | |
| 19.9B | 20.0B | 19.2B | 18.4B | 15.2B | 11.3B | 11.7B | 10.0B | 10.2B | 9.4B | 11.1B | |
Other operating expenses | 198M | 303M | — | — | — | — | — | — | — | — | — |
| Operating income | 13.7B | 10.0B | 8.2B | 3.8B | 1.1B | 5.2B | 2.9B | 3.4B | 3.7B | 4.9B | 4.1B |
Non-operating income | −1.34B | −1.31B | −1.29B | −1.26B | −1.32B | −1.25B | −1.38B | −1.39B | −1.45B | −1.35B | −1.05B |
| Pretax income | 12.4B | 8.7B | 6.9B | 2.5B | −265M | 3.9B | 1.5B | 2.0B | 2.2B | 3.6B | 3.1B |
Taxes | 2.18B | 1.66B | 0.94B | −0.79B | −0.38B | 0.72B | 0.21B | −0.16B | −0.77B | 53M | 0.24B |
| Net income | 10.2B | 7.0B | 6.0B | 3.3B | 112M | 3.2B | 1.3B | 2.2B | 3.0B | 3.5B | 2.8B |
| Diluted EPS | 6.54 | 9.00 | 7.62 | 4.22 | 0.16 | 4.88 | 2.06 | 3.40 | 4.74 | 5.52 | 4.46 |
| Diluted shares | 1.56B | 781.5M | 781.0M | 780.0M | 713.5M | 656.5M | 650.5M | 633.5M | 633.5M | 633.0M | 632.5M |
| Revenue growth | +8.6% | +18.0% | +3.3% | +18.5% | +40.6% | +9.2% | +10.4% | −1.7% | −2.3% | −6.9% | — |
| Gross margin | 81.9% | 81.1% | 82.0% | 72.1% | 66.8% | 80.1% | 79.8% | 77.7% | 80.8% | 82.1% | 81.2% |
| Operating margin | 23.4% | 18.5% | 17.9% | 8.5% | 2.8% | 19.4% | 12.0% | 15.3% | 16.4% | 21.3% | 16.7% |
| Net margin | 17.4% | 13.0% | 13.0% | 7.4% | 0.3% | 12.0% | 5.5% | 9.8% | 13.4% | 15.2% | 11.4% |